New Tiespectus Data in Treatment-Naïve nAMD

Clinical Report: New Tiespectus Data in Treatment-Naïve nAMD

Overview

Tiespectus, a bispecific Tie2 agonist and VEGF inhibitor, demonstrated significant improvements in visual acuity and retinal thickness in treatment-naïve patients with wet age-related macular degeneration (AMD). The phase 2 trial showed an average gain of over 7 letters in visual acuity by week 12, alongside a reduction in retinal thickness of over 215 µm.

Background

Wet age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, necessitating effective treatment options. Current standard therapies primarily target VEGF, but there is a need for novel agents that can enhance treatment efficacy. Tiespectus represents a new approach by combining VEGF inhibition with Tie2 pathway activation, potentially offering synergistic benefits.

Data Highlights

Parameter	Week 1	Week 12
Mean Change in Visual Acuity (letters)	5	7+
Reduction in Retinal Thickness (µm)	-	215+

Key Findings

Tiespectus is a bispecific agent targeting both VEGF and the Tie2 pathway.
The phase 2 trial involved 20 treatment-naïve eyes with wet AMD.
Patients received three initial monthly doses of tiespectus at doses of 7 mg and 10 mg.
Visual acuity improved by an average of 5 letters at week 1 and over 7 letters by week 12.
Retinal thickness decreased by over 215 µm by week 12.
No ocular adverse events related to tiespectus were reported in the trial.

Clinical Implications

The findings suggest that tiespectus may provide a promising new treatment option for patients with wet AMD, potentially leading to improved visual outcomes. Ongoing phase 3 trials will further elucidate its efficacy and safety profile.

Conclusion

Tiespectus shows significant potential in improving visual acuity and reducing retinal thickness in treatment-naïve wet AMD patients, warranting further investigation in larger trials.